tetano
Editor, Senior Moderator
Nature
. 2021 May 27.
doi: 10.1038/s41586-021-03653-6. Online ahead of print.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin[SUP] 1 2 [/SUP], Alexander Muik[SUP] 3 [/SUP], Isabel Vogler[SUP] 3 [/SUP], Evelyna Derhovanessian[SUP] 3 [/SUP], Lena M Kranz[SUP] 3 [/SUP], Mathias Vormehr[SUP] 3 [/SUP], Jasmin Quandt[SUP] 3 [/SUP], Nicole Bidmon[SUP] 3 [/SUP], Alexander Ulges[SUP] 3 [/SUP], Alina Baum[SUP] 4 [/SUP], Kristen E Pascal[SUP] 4 [/SUP], Daniel Maurus[SUP] 3 [/SUP], Sebastian Brachtendorf[SUP] 3 [/SUP], Verena Lörks[SUP] 3 [/SUP], Julian Sikorski[SUP] 3 [/SUP], Peter Koch[SUP] 3 [/SUP], Rolf Hilker[SUP] 3 [/SUP], Dirk Becker[SUP] 3 [/SUP], Ann-Kathrin Eller[SUP] 3 [/SUP], Jan Grützner[SUP] 3 [/SUP], Manuel Tonigold[SUP] 3 [/SUP], Carsten Boesler[SUP] 3 [/SUP], Corinna Rosenbaum[SUP] 3 [/SUP], Ludwig Heesen[SUP] 3 [/SUP], Marie-Cristine Kühnle[SUP] 3 [/SUP], Asaf Poran[SUP] 5 [/SUP], Jesse Z Dong[SUP] 5 [/SUP], Ulrich Luxemburger[SUP] 3 [/SUP], Alexandra Kemmer-Brück[SUP] 3 [/SUP], David Langer[SUP] 3 [/SUP], Martin Bexon[SUP] 6 [/SUP], Stefanie Bolte[SUP] 3 [/SUP], Tania Palanche[SUP] 3 [/SUP], Armin Schultz[SUP] 7 [/SUP], Sybille Baumann[SUP] 8 [/SUP], Azita J Mahiny[SUP] 3 [/SUP], Gábor Boros[SUP] 3 [/SUP], Jonas Reinholz[SUP] 3 [/SUP], Gábor T Szabó[SUP] 3 [/SUP], Katalin Karikó[SUP] 3 [/SUP], Pei-Yong Shi[SUP] 9 [/SUP], Camila Fontes-Garfias[SUP] 9 [/SUP], John L Perez[SUP] 10 [/SUP], Mark Cutler[SUP] 10 [/SUP], David Cooper[SUP] 10 [/SUP], Christos A Kyratsous[SUP] 4 [/SUP], Philip R Dormitzer[SUP] 10 [/SUP], Kathrin U Jansen[SUP] 10 [/SUP], Özlem Türeci[SUP] 3 [/SUP]
Affiliations
Abstract
BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavirus disease-19 (COVID-19)[SUP]1[/SUP]. Here we extend our previous phase 1/2 trial report[SUP]2[/SUP] and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). BNT162b2 elicited strong antibody responses, with SARS-CoV-2 serum 50% neutralizing geometric mean titers up to 3.3-fold above those observed in COVID-19 human convalescent samples (HCS) one week post-boost. BNT162b2-elicited sera neutralized 22 pseudoviruses bearing SARS-CoV-2 S variants. Most participants had a strong IFNγ- or IL-2-positive CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T helper type 1 (T[SUB]H[/SUB]1) T cell response, detectable throughout the full observation period of nine weeks following the boost. pMHC multimer technology identified several BNT162b2-induced epitopes that were presented by frequent MHC alleles and conserved in mutant strains. One week post-boost, epitope-specific CD8[SUP]+[/SUP] T cells of the early differentiated effector-memory phenotype comprised 0.02-2.92% of total circulating CD8[SUP]+[/SUP] T cells and were detectable (0.01-0.28%) eight weeks later. In summary, BNT162b2 elicits an adaptive humoral and poly-specific cellular immune response against epitopes conserved in a broad range of variants at well tolerated doses.
. 2021 May 27.
doi: 10.1038/s41586-021-03653-6. Online ahead of print.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin[SUP] 1 2 [/SUP], Alexander Muik[SUP] 3 [/SUP], Isabel Vogler[SUP] 3 [/SUP], Evelyna Derhovanessian[SUP] 3 [/SUP], Lena M Kranz[SUP] 3 [/SUP], Mathias Vormehr[SUP] 3 [/SUP], Jasmin Quandt[SUP] 3 [/SUP], Nicole Bidmon[SUP] 3 [/SUP], Alexander Ulges[SUP] 3 [/SUP], Alina Baum[SUP] 4 [/SUP], Kristen E Pascal[SUP] 4 [/SUP], Daniel Maurus[SUP] 3 [/SUP], Sebastian Brachtendorf[SUP] 3 [/SUP], Verena Lörks[SUP] 3 [/SUP], Julian Sikorski[SUP] 3 [/SUP], Peter Koch[SUP] 3 [/SUP], Rolf Hilker[SUP] 3 [/SUP], Dirk Becker[SUP] 3 [/SUP], Ann-Kathrin Eller[SUP] 3 [/SUP], Jan Grützner[SUP] 3 [/SUP], Manuel Tonigold[SUP] 3 [/SUP], Carsten Boesler[SUP] 3 [/SUP], Corinna Rosenbaum[SUP] 3 [/SUP], Ludwig Heesen[SUP] 3 [/SUP], Marie-Cristine Kühnle[SUP] 3 [/SUP], Asaf Poran[SUP] 5 [/SUP], Jesse Z Dong[SUP] 5 [/SUP], Ulrich Luxemburger[SUP] 3 [/SUP], Alexandra Kemmer-Brück[SUP] 3 [/SUP], David Langer[SUP] 3 [/SUP], Martin Bexon[SUP] 6 [/SUP], Stefanie Bolte[SUP] 3 [/SUP], Tania Palanche[SUP] 3 [/SUP], Armin Schultz[SUP] 7 [/SUP], Sybille Baumann[SUP] 8 [/SUP], Azita J Mahiny[SUP] 3 [/SUP], Gábor Boros[SUP] 3 [/SUP], Jonas Reinholz[SUP] 3 [/SUP], Gábor T Szabó[SUP] 3 [/SUP], Katalin Karikó[SUP] 3 [/SUP], Pei-Yong Shi[SUP] 9 [/SUP], Camila Fontes-Garfias[SUP] 9 [/SUP], John L Perez[SUP] 10 [/SUP], Mark Cutler[SUP] 10 [/SUP], David Cooper[SUP] 10 [/SUP], Christos A Kyratsous[SUP] 4 [/SUP], Philip R Dormitzer[SUP] 10 [/SUP], Kathrin U Jansen[SUP] 10 [/SUP], Özlem Türeci[SUP] 3 [/SUP]
Affiliations
- PMID: 34044428
- DOI: 10.1038/s41586-021-03653-6
Abstract
BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavirus disease-19 (COVID-19)[SUP]1[/SUP]. Here we extend our previous phase 1/2 trial report[SUP]2[/SUP] and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). BNT162b2 elicited strong antibody responses, with SARS-CoV-2 serum 50% neutralizing geometric mean titers up to 3.3-fold above those observed in COVID-19 human convalescent samples (HCS) one week post-boost. BNT162b2-elicited sera neutralized 22 pseudoviruses bearing SARS-CoV-2 S variants. Most participants had a strong IFNγ- or IL-2-positive CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T helper type 1 (T[SUB]H[/SUB]1) T cell response, detectable throughout the full observation period of nine weeks following the boost. pMHC multimer technology identified several BNT162b2-induced epitopes that were presented by frequent MHC alleles and conserved in mutant strains. One week post-boost, epitope-specific CD8[SUP]+[/SUP] T cells of the early differentiated effector-memory phenotype comprised 0.02-2.92% of total circulating CD8[SUP]+[/SUP] T cells and were detectable (0.01-0.28%) eight weeks later. In summary, BNT162b2 elicits an adaptive humoral and poly-specific cellular immune response against epitopes conserved in a broad range of variants at well tolerated doses.